Drug Type Small molecule drug |
Synonyms GSK 372475, GSK-372475, NS 2359 |
Target |
Mechanism Dopamine reuptake inhibitors, Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H19Cl2NO |
InChIKeyFPTPUYCHSWIWIB-FUTJPDQTSA-N |
CAS Registry195875-87-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cocaine-Related Disorders | Phase 2 | US | 01 May 2016 | |
Depressive Disorder | Phase 2 | AU | 01 Apr 2007 | |
Depressive Disorder | Phase 2 | BE | 01 Apr 2007 | |
Depressive Disorder | Phase 2 | EE | 01 Apr 2007 | |
Depressive Disorder | Phase 2 | FI | 01 Apr 2007 | |
Depressive Disorder | Phase 2 | SK | 01 Apr 2007 | |
Depressive Disorder | Phase 2 | ZA | 01 Apr 2007 | |
Depressive Disorder, Major | Phase 2 | BG | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | CA | 19 Dec 2006 | |
Depressive Disorder, Major | Phase 2 | CL | 19 Dec 2006 |
Phase 2 | 55 | (NS2359) | pfidrvyqde(alogxwxtbz) = mxoqamlfqa jxxusfrqyt (nerelawegd, nrwvjbhzse - nkxzptxxrc) View more | - | 24 May 2021 | ||
placebo (Placebo) | pfidrvyqde(alogxwxtbz) = tevmxqquxb jxxusfrqyt (nerelawegd, rlsmcurvvw - wuahbnrkej) View more | ||||||
Phase 2 | 492 | Placebo | irrfczaigg(mffdskmvhe) = shbczkzacv hlgwieycnz (faaeyeslts, mupuzwdmzr - ikopcogwsm) View more | - | 05 Feb 2018 |